| ［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
［2］ Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non smal cell lung cancer［J］. N Engl J Med, 2018, 378(2): 113-125. DOI: 10.1056/NEJMoa1713137.
［3］ Hendriks L, Besse B. New windows open for immunotherapy in lung cancer［J］. Nature, 2018, 558(7710): 376-377. DOI: 10.1038/d41586-018-05312-9.
［4］ 卢佳利, 叶自亮, 陈晓菊, 等. 培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗中国晚期初治非小细胞肺癌的meta分析［J］. 转化医学电子杂志, 2018, 5(12): 11-16. DOI: 10.12095/j.issn.2095-6894.2018.12.003.
［5］ Folkman J. Tumor angiogenesis: therapeutic implications［J］. N Engl J Med, 1971, 285(21): 1182-1186. DOI: 10.1056/NEJM197111182852108.
［6］ O′Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth［J］. Cell, 1997, 88(2): 277-285.
［7］ Poluzzi C, Iozzo RV, Schaefer L. Endostatin and endorepellin: a common route of action for similar angiostatic cancer avengers［J］. Adv Drug Deliv Rev, 2016, 97: 156-173. DOI: 10.1016/j.addr.2015.10.012.
［8］ Xiao L, Yang S, Hao J, et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis［J］. Cancer Lett, 2015, 359(1): 148-154. DOI: 10.1016/j.canlet.2015.01.012.
［9］ Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (review)［J］. Mol Med Rep, 2018, 17(6): 8019-8030. DOI: 10.3892/mmr.2018.8922.
［10］ Xu X, Mao W, Chen Q, et al. Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/β-catenin signaling pathway［J］. PLoS One, 2014, 9(9): e107463. DOI: 10.1371/journal.pone.0107463.
［11］ Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy［J］. Science, 2005, 307(5706): 58-62. DOI: 10.1126/science.1104819.
［12］ Jia H, Kling J. China offers alternative gateway for experimental drugs［J］. Nat Biotechnol, 2006, 24(2): 117-118. DOI: 10.1038/nbt0206-117.
［13］ Ning T, Jiang M, Peng Q, et al. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model［J］. Thorac Cancer, 2012, 3(3): 229-238. DOI: 10.1111/j.1759-7714.2012.00111.x.
［14］ 何朗, 孙永红, 蒋莉, 等. rh-Endostatin与肿瘤血管正常化时相的关系初探［J］. 中华肿瘤防治杂志, 2016, 23(19): 1291-1297. DOI: 10.16073/j.cnki.cjcpt.2016.19.004.
［15］ Wang J, Sun Y, Qin S, et al. Results of phase Ⅳ clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC)［J］. J Clin Oncol, 2010, 28 Suppl 15: a7598. DOI: 10.1200/jco.2010.28.15_suppl.7598.
［16］ 周青, 胡静雯, 尹荣, 等. 重组人血管内皮抑素静脉泵入联合窗口期化疗治疗晚期非小细胞肺癌的临床观察［J］. 临床肿瘤学杂志, 2014, 19(12): 1113-1117.
［17］ 刘丹. 恩度持续泵入联合化疗治疗中晚期非小细胞肺癌的疗效观察［D］. 青岛: 青岛大学, 2018.
［18］ 辛刚, 杜鹃, 朱琳, 等. 顺铂与重组人内皮抑素不同联合用药方案对裸鼠卵巢癌的疗效［J］. 中华医学杂志, 2011, 91(47): 3367-3370. DOI: 10.3760/cma.j.issn.0376-2491.2011.47.014.
［19］ Kubota Y. Tumor angiogenesis and anti-angiogenic therapy［J］. Keio J Med, 2012, 61(2): 47-56. DOI: 10.2302/kjm.61.47. |
